Trinity Biotech PLC Schedule 13G shows Novus Diagnostics Ltd. reports beneficial ownership of 1,119,988 American Depositary Shares, representing 5.99% of the ADS class based on 18,710,000 ADS outstanding as reported. The filing states Novus has sole voting and dispositive power for these 1,119,988 ADS.
Positive
None.
Negative
None.
Insights
Major holder reports a near-6% stake with sole voting power.
Novus Diagnostics Ltd. is disclosed as beneficial owner of 1,119,988 ADS, with sole voting and dispositive authority, representing 5.99% of the class based on the issuer's reported 18,710,000 ADS outstanding.
Holder disclosures like this indicate an institutional stake; subsequent filings would clarify whether this is passive (13G) or subject to change.
Disclosure follows Section 13 reporting norms; no transaction details provided.
The filing lists the ownership amount and voting/dispositive powers but does not describe purchases, sales, or timing. It includes a standard disclaimer about pecuniary interest and the reporting persons' disclaimers under Sections 13(d)/16.
Further Schedule 13D or Form 4 filings would be required to show active engagement or transactions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TRINITY BIOTECH PLC
(Name of Issuer)
@Class 'A' Ordinary Shares represented by American Depositary Shares
(Title of Class of Securities)
12/23/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Novus Diagnostics Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
IRELAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,119,988.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,119,988.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,119,988.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) Based on 18,710,000 American Depository Shares outstanding as reported by the Issuer. Each American Depositary Share reported on this Schedule 13G represents four Class 'A' Ordinary Shares.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TRINITY BIOTECH PLC
(b)
Address of issuer's principal executive offices:
IDA Business Park, Bray, Co. Wicklow, Ireland
Item 2.
(a)
Name of person filing:
Novus Diagnostics Ltd.
(b)
Address or principal business office or, if none, residence:
Entity: Delaware limited liability company, United States
(d)
Title of class of securities:
@Class 'A' Ordinary Shares represented by American Depositary Shares
(e)
CUSIP No.:
896438306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
(b)
Percent of class:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
(ii) Shared power to vote or to direct the vote:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
(iii) Sole power to dispose or to direct the disposition of:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
(iv) Shared power to dispose or to direct the disposition of:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The amounts of securities reported as beneficially owned on this Schedule 13G are the number of American Depositary Shares that may be deemed to be beneficially owned by the Reporting Persons. Each American Depositary Share represents four of the Issuer's Class 'A' Ordinary Shares.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Novus Diagnostics Ltd.
Signature:
/s/ Keith O'Neill
Name/Title:
Keith O'Neill/Chief Executive Officer
Date:
03/06/2026
Comments accompanying signature: The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and this report shall not otherwise be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 13(d) or Section 16 of the Exchange Act.
What stake does Novus Diagnostics report in TRINITY BIOTECH (TRIB)?
Novus Diagnostics reports ownership of 1,119,988 ADS, equal to 5.99% of the ADS class based on 18,710,000 ADS outstanding as reported in the filing.
Does Novus Diagnostics have voting control over the TRINITY BIOTECH shares?
Yes. The filing states Novus has sole voting power and sole dispositive power for the reported 1,119,988 ADS, indicating control over votes and dispositions for those ADS.
Is this Schedule 13G a sign that Novus plans to actively influence TRINITY BIOTECH?
A Schedule 13G generally indicates passive ownership when timely filed; the provided excerpt lists holdings and powers but does not state activist intent or planned transactions.
How was the 5.99% ownership calculated in the filing?
The percentage is based on the issuer's report of 18,710,000 American Depositary Shares outstanding and the reported 1,119,988 ADS held by Novus Diagnostics.
Does each ADS equal one Trinity Biotech Class 'A' share?
No. The filing specifies that each American Depositary Share represents four Class 'A' Ordinary Shares, so ADS counts reflect that conversion ratio.
